Every dollar you spend is a trade-off. A dollar spent on one thing is a dollar that is not available for the next. 

Some of that money costs ownership. When it does, overspending means founders and early investors give up a bigger share of what they built through dilution.

That is why the instinct to cut costs is a good one. But skipping a key step does not make it free. It makes it late, and having to rush later may cost more in the long run. 

There is a different way: the scrappy startup. Our goal is to help you keep more of your return, while bringing more products to the patients who need them. 

Same outcome, less spend 

Scrappy means reaching the same outcome with less. It never means skipping the work. 

A founder who asks, “What is the least we can spend?” will eventually cut something that mattered. A founder who asks, “What do we need to know before we spend the next dollar?” will spend less and learn more. 

In practice, scrappy teams find a creative route to the data they need instead of buying the biggest study first. They bring in expertise at the exact moment they need it, not a full team before they do. They sequence work so each step answers a question the next step depends on. And, they choose between going faster and spending more money, rather than having that choice put on them. 

What a skipped step really looks like 

We often see steps skipped in these five areas within early-stage medtech.

Design and development. If you build before design inputs and requirements are clear, you’ll often have to revisit the design later. Those inputs typically come from early market research: talking with the people who will use the device, learning their workflow and understanding the current standard of care. Without clear inputs, an update after design freeze can mean more testing, updating documentation and pushing out the timeline. The questions to ask early are what the device must do, for whom and under what conditions. 

Regulatory and quality. You don’t need to answer every regulatory question on day one but general direction and testing requirements are key. You can design in ways that will make testing easier and cheaper, saving you time, money and risk. A full-blown quality system while you’re in discovery doesn’t make sense but if it’s an afterthought you’ll be reconstructing records that should have been created as the work happened. The questions to ask early are which pathway is likely, whether a predicate device exists, what evidence the pathway (for FDA and market adoption) will need and which records need to exist from day one.  

Clinical and evidence. If you plan your study before you are clear on the questions, your data may not answer what regulators, clinicians or investors need to act. Evidence also does more than support a submission, it can differentiate you in the market. The questions to ask early are what decision the data needs to support and who will rely on it.

Manufacturing and commercial.  Leaving supplier choices and cost of goods until late can crush your margin. Simplicity wins: fewer parts and materials mean fewer assemblies and less waste. In the same vein, if you wait to think about commercialization until after clearance, your product may not be clearly positioned for the buyer. Know who the customer is, what they will pay for and why. The questions to ask early are what the product can realistically cost to build, which market comes first and what a buyer needs to see before saying yes.

Fundraising. If you raise money before the milestone that justifies it, or from a source that does not fit the plan, you may find yourself raising again sooner than expected, or more diluted than you need to be. Make sure to define your investors and approach them as sales targets. The questions to ask early are what milestone this raise will reach and what investors will need to see by then.

Ignorance of the law is not a defense 

Most founders do not skip steps on purpose. They skip them because they didn’t know it was a step. 

If you’re a first-time founder, you may not know what the process looks like from concept to commercialization. You can’t yet judge which steps are essential and which can be right-sized. Even experienced entrepreneurs hit this wall when they move into a new device type, a new market or a new stage of company growth. 

Without a map, every decision feels equally urgent and risky. That is where a co-pilot who has been through it before comes in. We help medtech startups get products to market as quickly and efficiently as possible. But we are also entrepreneurs, and we have lived through these trade-offs ourselves. We know what it feels like to choose between speed and cash, and what it costs when a decision turns out to be the wrong one. 

That lived experience lets us show founders the route, point out the steps ahead and explain why each one matters, so they decide with open eyes. 

“Surrounding yourself with people that have navigated the path before you successfully is paramount. My advisors have pointed out a number of potential problems before they became a reality. It helped me allocate my capital, move faster and have a higher quality output,” said Morgan Evans, Co-Founder and CEO, Agitated Solutions and Founder, Avio Medtech.

Leveraging expertise too expensive to hire full time 

Your biggest decisions are often the ones no one on the team has had to make before. How to structure the next raise. How to model sales. How to think about the financial picture without a full-time finance leader. 

A full-time executive in those roles is out of reach for most early-stage teams. A fractional leader is not. Bringing in a seasoned leader at the right time lets you leverage senior expertise when its needed and turn it off when it’s not. 

Through our Navigator Network, founders can work with experienced medtech executives and founders as strategic co-pilots. The role is part player and part coach. A Navigator gives strategic guidance and also takes work off the founder’s plate. 

“Avio has been an amazing force multiplier to my company. Their team embodies collaboration and expertise, guiding us through the process [of bringing our device to market,]” said Andy Orbst, President, Fistula Solution.

Timing matters here as much as skill. A fractional leader brought in early can help shape the plan.

The common thread: spend when it answers a question 

Everything comes back to timing. Money spent before a question is ready to be answered gets wasted. Money spent after a skipped step causes rework. The strongest teams put each dollar where it unlocks the next decision. 

That takes a plan, and it takes someone willing to pressure-test it early. Design, regulatory, quality, clinical, manufacturing, reimbursement, commercial and fundraising choices all touch each other. A cheap call in one area becomes an expensive problem in another. 

The founders we admire most are not the ones who spent the least. They are the ones who got the most out of every dollar and still did the work that matters. 

Reach out to talk through how we can help your team make every dollar count. 

FAQ 

What does scrappy mean for a medtech startup? 

Scrappy means reaching the same outcome with fewer resources, not reaching a cheaper outcome by skipping necessary work. It rewards creativity, sequencing and good timing. It does not reward cutting steps that will need to be repeated later. 

How does overspending affect a startup’s funding and ownership? 

Startups fund their work from several sources, including venture capital, family offices, grants and other non-dilutive funding. Every source is limited, so overspending shortens runway and can mean raising again sooner. When the new money is equity, it also means founders and early investors give up more ownership. 

What is rework in medtech product development? 

Rework is the time and money spent going back to redo something, such as a design change, repeated testing or rewritten documentation. It often happens when decisions are made in the wrong order or before the information needed to make them is available. 

When does it make sense to hire a fractional leader instead of a full-time executive? 

A fractional leader fits when a company needs senior expertise for a defined stretch of time, such as preparing for a raise, building financial strategy or planning a market launch. It gives a startup access to senior experience without the full-time headcount.

How can a startup get the data it needs without running the biggest study first? 

You can start by asking which decision the data must support, then look for the smallest credible source that answers it. Existing evidence, focused testing or a smaller early study may inform the next step. The right path depends on the product and the regulatory context.